Company: QTIWW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001844505-25-000038
Chunk: 4

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 4
---
 build strong manufacturing processes to deliver the QT Breast Scanners in large scale production.

Our Competitive Strengths

We believe that our competitive strengths include the following: 

•The world-wide market for medical imaging is large and it has a potential to expand in the areas where the Company has differentiation; 

•a non-ionizing, non-contrast dye injection imaging modality; 

•an imaging modality with superior performance as compared to traditional mammogram with respect to specificity (false positive), thus less unnecessary emotional trauma for patients, reduced numbers of invasive follow-up procedures and a reduction of costs for both patient and broader society; 

•an imaging modality with the potential to offer superior specificity compared to screening breast MRI for younger women (under 40 years of age) at above-average risk. By reducing false positives, it holds the potential of sparing patients from undue emotional distress, limiting unnecessary biopsies and follow-up procedures, and ultimately decreasing healthcare costs for both individuals and society;

•a lower price point than conventional high-energy imaging equipment; 

•the Company’s technology can be deployed to LREs because of its automation, small footprint, no shielding, no contrast-dye injection; 

•the Company’s technology is portable and can be used in POC settings such as LREs; 

•the Company’s technology is deployable in outdoor settings such as sports, military, and naval settings; 

•the Company’s technology reduces the barriers to testing and follow up-care for women, as there is no need for specialized training and the technology is well-suited for lowering health care costs by being affordable and easily accessed; 

•the Company’s technology provides optimized patient experience, as no radiation is involved, with the patient being able to be followed with no limitation to imaging frequency; 

•the Company’s technology is well-suited for traditional tertiary care hospitals and additionally for DTC and DTP applications, that are outside these institutions; 

•the Company’s technology is uniquely proprietary, disruptive and a one-of-a kind product that can address a variety of unmet medical needs in the medical marketplace; 

•the Company’s scanner features a uniquely simple design with a small number of components, which in turn significantly reduces the cost of the bill-of-materials (“BOM”), cost-of-good-sold (“COGS”), and the total-cost-of-ownership, and enables a lower average sales price (“ASP”) compared to other available systems, thus making it much more affordable to large mass deployments; and 

•the Company’s products have potential strong